

1 Autoimmunity, Antibody Dependent COVID-19 Enhancement and Other Risks of SARS
2 CoV-2 Vaccination: Beneath the Tip of the Iceberg.

3 Mina T. Kelleni, MD, PhD

4 Pharmacology Department, College of Medicine, Minia University, Egypt

5 mina.kelleni@mu.edu.eg; drthabetpharm@yahoo.com

6 Mobile: +201200382422

7 <https://orcid.org/0000-0001-6290-6025>

8 Highlights

9 Since August 2020 and till today, numerous “reputable” medical journals have denied this
10 manuscript a fair opportunity to be peer reviewed.

11 Some SARS CoV-2 vaccines have been investigated and all have not been fully approved.
12 SARS CoV-2 vaccines might induce autoimmunity that could be fatal.

13 SARS CoV-2 induced antibody dependent enhancement has not been excluded yet.

14 An informed personalized risk benefit ratio before receiving SARS CoV-2 vaccines must
15 be secured.


16 Abstract

17 mRNA based and adenovirus vectored vaccines, were first ever or first commercially ever
18 approved for the public, respectively. However, these new types possess a potential risk to
19 induce auto-immune diseases e.g., thrombocytopenia and some of these complications
20 might also reason for some of the post vaccination sudden death reports e.g., autoimmune
21 myocarditis and immune induced thrombosis and thromboembolism. Moreover, all SARS
22 CoV-2 types of vaccines, depending on the spike protein immunogenicity, especially the
23 conventional inactivated ones might increase the likelihood of COVID-19 severity upon
24 re-infection through antibody dependent enhancement which might reason for the recently
25 described abundance of hospital admissions within seven days of vaccination and might
26 also reason for some of the serious adverse effects encountered with administration of
27 convalescent plasma to COVID-19 patients. Furthermore, SARS CoV-2 vaccines might

share in development of some lethal SARS CoV-2 variants. Finally, we suggest that making these COVID-19 vaccines compulsory or administering them to children or pregnant participants might be considered as a crime against humanity and an informed personalized risk benefit ratio especially for described high risk groups must be secured.

Keywords: COVID-19, SARS CoV-2, Oxford/AstraZeneca ChAdOx1 nCoV-19 vaccine, Johnson & Johnson Ad26.COV2-S vaccine, Pfizer-BioNTech BNT162b2 vaccine, Moderna mRNA-1273 vaccine, Autoimmune diseases, Antibody dependent enhancement, SARS CoV-2 B.1.617 variants, Vaccine passports.

Graphical abstract



Introduction

Safe COVID-19 vaccines are considered of utmost importance to stem SARS CoV-2 current pandemic [1]. However, the unprecedented accelerated timelines to develop COVID-19 vaccines have necessitated a critical call for active pre- and post-licensure safety surveillance systems to properly investigate potential adverse effects or toxicities [1-3]. Importantly, whether the incidence of SARS CoV-2 vaccine related serious adverse effects might be considered rare or less rare [4,5], or very difficult to be prove causation[6], the scientific community has an obligation to continue developing new standards for safety monitoring. Notably, in a recent report, even the high risk groups to develop COVID-19 complications might not eventually benefit from SARS CoV-2 vaccines as previously was expected and repeatedly advertised and we consider this report [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/982499/S1208_CO-CIN_report_on_impact_of_vaccination_Apr_21.pdf?fbclid=IwAR1wKZUaG9UOgYMsvwbeQatY-aLG3eRz0mYFAMQxY5QF4xn3hlmtZxGWIV0] though considered of low evidence, at least currently, a rare one as regards to its high scientific integrity which is free of a potential economic bias. Similarly, almost half of the deaths in UK due to the delta variant were among fully vaccinated patients above 50 years old [<https://www.businessinsider.com/vaccinated-among-delta-deaths-but-older-relatively-few-uk-data-2021-6>]. Moreover, the Oxford/AstraZeneca ChAdOx1 nCoV-19 vaccine has been recently shown to be ineffective as regards to prevention of mild-moderate COVID-19 due to the B.1.351 South African variant[7]. Similarly, though all the propaganda that promotes studies with serious limitations and bias, scientific integrity still emphasizes the known fact that the current COVID-19 systemic vaccination is not likely to prevent nasal SARS-CoV-2 infection and asymptomatic transmission[8].

In this manuscript, we briefly discuss the potential autoimmune adverse effects of SARS CoV-2 nucleic acid-based vaccines; adenovirus vectored and mRNA vaccines. Furthermore, we also briefly discuss the potential risk to develop more severe COVID-19 upon SARS CoV-2 reinfection after vaccination as compared to the natural infection; a phenomenon called antibody dependent disease enhancement and its potential association

with adverse effects encountered while convalescent plasma was administered to COVID-19 patients. Finally, we illustrate, from our point of view, some of the higher risk groups to develop autoimmune disorders urging that they might consider a personalized risk benefit ratio as well as some potential tools that might decrease this potential.

We wish to confirm that the public has a moral, legal, and constitutional right to know all the potential hazards of COVID-19 newly emergency approved vaccines including even the rarest ones to allow an informed personalized risk benefit ratio to be weighed to freely decide whether to receive any or not. This right should never be argued or suppressed as, unfortunately, it appeared as the case when a professional peer review for this and other related preprinted manuscripts has been denied a non-biased peer review opportunity by numerous well reputed medical journals since August 2020 (Nature Medicine "Why smokers should not hurry to be vaccinated with SARS CoV-2 mRNA vaccine?" (NMED-C108161) when I first tried to submit it to a journal before its first preprint at Authorea on November 2020[9].

Adenovirus vectored vaccines potential autoimmunity risk

Autoimmunity developing due to similarities between viral and human proteins is one of the known sequelae of viral infections that include short term and sometimes permanent damage to the CNS[10]. Moreover, an increased autoimmunity risk was hypothesized due to the inclusion of new adjuvants into the already approved licensed vaccines[11]. However, this risk associated with COVID-19 vaccines especially the newly approved SARS CoV-2 ones is yet to be discovered.

Notably, adenovirus vectored SARS CoV-2 vaccine has been first commercially approved to be used in humans in Russia which is currently undergoing a mass vaccination program and on December 30, 2020, it has also been announced to be authorized for emergency supply in the UK followed by other countries and since that date millions of jabs have been administered basing on emergency not full approval.

Importantly, two adenovirus vectored SARS CoV-2 vaccine global phase III clinical trials were temporarily paused due to reports of serious adverse medical events of autoimmune and/or inflammatory complications including multiple sclerosis and transverse myelitis

which were ultimately deemed to be unrelated to the SARS CoV-2 vaccine. Moreover, lack of transparency concerns have been raised as the involved companies declined the release of the thorough details of these serious adverse events claiming patients' privacy issues [12-15] and a sharp criticism of the analysis of the results of one trial including a serious dose mistake that involved thousands of patients, claimed later to be a "beneficial" one, has also been raised[16]. Importantly, supraphysiological expression levels of spike proteins in some individuals who receive nucleic acid based vaccination might share in development of autoimmune reactions [17] and we recommend that the dose of the nucleic acid based vaccines, if decided to be received, should be optimized to the lowest possible dose and potential tools to prevent induced autoimmunity should be further developed and tested. In addition, we also suggest that a skewed immune virus spike protein-antibody complex might trigger and reason, at least partly, for this potential autoimmunity [18].

mRNA vaccines potential autoimmunity risk

mRNA based vaccines, first approved in UK for COVID-19 as a first ever approval for this novel type of vaccination in a western country to be followed by USA, the European Medicines Agency (EMA) as well as several countries worldwide, possess multiple theoretical and manufacturing advantages over traditional subunit, live attenuated and killed virus vaccines[19-21]. However, their remarkable high efficacy in SARS CoV-2 clinical trials contradicted the results of other previous clinical trials using mRNA vaccines to prevent H10N8, H7N9 influenza and rabies viruses which have been lower than what was expected when compared to those of their preclinical studies[20]. Moreover, though mRNA vaccines encoding HIV and CMV antigens elicited antigen-specific CD4+ and CD8+ T cell immune responses; no reduction in viral load was observed[19].

Importantly, potential risks of mRNA, and saRNA, based vaccines include risk of autoimmunity due to development of autoreactive antibodies of any non-native nucleotides and delivery system components. Furthermore, the identification of individuals at an increased risk of autoimmune reactions before mRNA vaccination was advised [20,22,23]. Notably, other than the currently known potential risks of anaphylaxis or Bell's palsy (<https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html>), soon after mRNA based SARS CoV-2 vaccine approval, the Norwegian Medicines Agency

started to investigate the potential causation of Pfizer-BioNTech mRNA (BNT162b2) vaccine against Covid-19 and the death of 75-year-old and elder 33 recipients. Similarly, the Paul Ehrlich Institute in Germany has been reported to investigate 10 fatalities that occurred within four days of vaccination and whose age groups were not revealed to the public but described as previously seriously ill patients suffering from many underlying diseases[24]. Alarming, though attributing these fatalities to commonly encountered adverse effects in the elderly is usually advocated, yet an American 12-year-old female volunteer for BNT162b2 has suffered paralysis (transverse myelitis? Guillain-Barré?) and a piece of news of her was only publicly released very late and only after hundreds of millions of jabs have been administered [<https://www.fox6now.com/news/senator-johnson-families-speak-covid-vaccine-adverse-reactions>]. Similarly, an otherwise healthy 56-year-old American obstetrician and gynecologist has developed autoimmune thrombocytopenia three days after receiving BNT162b2 vaccine and later he was deceased of brain hemorrhage as a complication to this autoimmune disease. Similarly, another American 60-year-old X-ray technologist was deceased four days after taking his second dose of the BNT162b2 vaccine, he complained of an acute abdominal pain and dyspnea and tested negative for COVID-19, later his condition deteriorated, was put into a medically induced coma and a ventilator. He eventually suffered from severe hypotension before death. Other than overweight and hypertension, he has not complained of any concomitant disorder. Moreover, at least one participant in the clinical trials has suffered from cardiac arrest (<https://www.reuters.com/article/uk-factcheck-pfizer-health-concerns-idUSKBN28K2R6>) and an otherwise healthy 41-year-old Portuguese nurse was found dead two days after receiving BNT162b2 vaccine. Similarly, an analysis has seriously doubted the integrity of the safety data reported by the Israeli ministry of health as regards to its adopted policy for mass vaccination with BNT162b2 vaccine [http://www.nakim.org/israel-forums/viewtopic.php?t=270812&s=The_uncovering_of_the_vaccination_data_in_Israel_reveals_a_frightening_picture&fbclid=IwAR3qTWwbnGVhmkhjOqDktSaYB_QAGTBkk1SETlrXS0GJvDOMMXl5W8qPjuA] and an informal weak criticism of this report has confirmed the validity of its statistics [<https://www.lesoleil.com/actualite/verification-faute/verification-faute-un-vaccin-qui-aggrave-les-symptomes-vraiment->

653bb8c18253322defd076a115d8a83e]. Additionally, another report claims that post BNT162b2 mass vaccination increased Israeli all-cause mortality with an observational “murky wave of heart attacks” as well as suggestions of intended official lack of transparency [https://swprs.org/israel-why-is-all-cause-mortality-increasing/?fbclid=IwAR0WX4OUR67KWZrxpVqBmV5Z_Xhl114cJv4wCqJo2BzF_Fd7kbnWXg6LHo4]. Interestingly, though the official statements deny a single post SARS CoV-2 vaccination mortality [https://www.reuters.com/article/uk-factcheck-israel-idUSKBN2AA2TS], unofficial reports strongly contradict this claim [https://www.facebook.com/lindsayfoord/videos/10157458591032391]. Recently, Israeli authorities have announced a probable link between the second dose of BNT162b2 vaccine and myocarditis in young men aged 16 to 19 than in other age groups [https://www.reuters.com/world/middle-east/israel-sees-probable-link-between-pfizer-vaccine-small-number-myocarditis-cases-2021-06-01/] and one also recommends independent international investigations for the best interests of transparency and this should also apply to the alarming claims about the actual potential SARS CoV-2 vaccine related mortalities [https://austingwalters.com/covid19-vaccine-risks/] or that the CDC has manipulated this actual number [https://www.americanthinker.com/blog/2021/06/what_is_the_true_number_of_vaccine-related_deaths.html] as well as that the FDA has chosen not to require SARS CoV-2 vaccines’ manufacturers post marketing more rigorous safety data capturing as claimed by inventor of the mRNA vaccine technology Dr. Robert Malone [https://www.bitchute.com/video/wUlpFIXb3KSz/].

Adenovirus vectored and mRNA vaccines mutual autoimmune risks.

Importantly, immune thrombocytopenia was previously attributed to IgG opsonized dengue virus complexes bound to Fc receptors in platelets which were also suggested to play a central role in development of antibody dependent enhancement during dengue infection[25] and we suggest that the same mechanism might also apply to reason for the reported post BNT162b2 and Moderna mRNA-1273 SARS CoV-2 mRNA vaccination induced thrombocytopenia [https://www.nytimes.com/2021/02/08/health/immune-thrombocytopenia-covid-vaccine-blood.html] that also led the EMA to start a review of

193 safety signal in patients who received any of BNT162b2, mRNA-1273 and
194 Oxford/AstraZeneca (ChAdOx1 nCoV-19) (adenovirus vectored) vaccines
195 [[https://www.reuters.com/article/brief-ema-reviews-safety-signal-of-immun-](https://www.reuters.com/article/brief-ema-reviews-safety-signal-of-immun-idUSFWN2LA0PH)
196 [idUSFWN2LA0PH](https://www.reuters.com/article/brief-ema-reviews-safety-signal-of-immun-idUSFWN2LA0PH)]. Moreover, autoantibody induced thrombosis was previously
197 described in another setting[26] as well as other potential mechanisms for
198 immunothrombosis[27] and venous thromboembolism was shown to be consistently
199 associated with autoimmune diseases[28].

200 Taken together, we suggest that a dysregulated autoimmunity might be triggered in some,
201 genetics might play a role, individuals who received SARS CoV-2 vaccines leading to
202 sudden death from thromboembolism. Notably, though ChAdOx1 nCoV-19 vaccine has
203 been first put under investigations because of multiple simultaneous fatality reports that
204 led some European countries to halt its administration, permanently, or temporarily, as
205 becoming usual, while claiming unscientifically valid similar incidence in the general
206 population [[https://www.dw.com/en/covid-several-european-countries-halt-use-of-](https://www.dw.com/en/covid-several-european-countries-halt-use-of-astrazeneca-vaccine/a-56835406)
207 [astrazeneca-vaccine/a-56835406](https://www.dw.com/en/covid-several-european-countries-halt-use-of-astrazeneca-vaccine/a-56835406)] as the abstract facts refute this claim and declare that
208 these vaccine related extremely serious adverse effects are more frequent than would be
209 expected by chance [[https://www.sciencemag.org/news/2021/03/it-s-very-special-picture-](https://www.sciencemag.org/news/2021/03/it-s-very-special-picture-why-vaccine-safety-experts-put-brakes-astrazeneca-s-covid-19?utm_campaign=news_daily_2021-03-17&et rid=181260252&et cid=3703486)
210 [why-vaccine-safety-experts-put-brakes-astrazeneca-s-covid-](https://www.sciencemag.org/news/2021/03/it-s-very-special-picture-why-vaccine-safety-experts-put-brakes-astrazeneca-s-covid-19?utm_campaign=news_daily_2021-03-17&et rid=181260252&et cid=3703486)
211 [19?utm_campaign=news_daily_2021-03-17&et rid=181260252&et cid=3703486](https://www.sciencemag.org/news/2021/03/it-s-very-special-picture-why-vaccine-safety-experts-put-brakes-astrazeneca-s-covid-19?utm_campaign=news_daily_2021-03-17&et rid=181260252&et cid=3703486)].

212 Notably, arterial, venous thrombotic, or embolic events were recently reported in the South
213 African Ad26.COV2.S Vaccine Study [5] and the reported cerebral venous sinus
214 thrombosis, encountered post ChAdOx1 nCoV-19 vaccination
215 [[https://www1.racgp.org.au/newsgp/clinical/atagi-review-of-astrazeneca-covid-vaccines-](https://www1.racgp.org.au/newsgp/clinical/atagi-review-of-astrazeneca-covid-vaccines-what-gp)
216 [what-gp](https://www1.racgp.org.au/newsgp/clinical/atagi-review-of-astrazeneca-covid-vaccines-what-gp)] was previously described with autoimmune thyroiditis/hypothyroidism [29] and
217 its risk factors include the presence of autoantibodies like antiphospholipid and
218 anticardiolipin antibodies[30]. Moreover, some scientists from Norway and Germany have
219 independently confirmed the ability of ChAdOx1 nCoV-19 to trigger this autoimmune
220 reaction [[https://www.wsj.com/articles/scientists-say-they-found-cause-of-blood-clotting-](https://www.wsj.com/articles/scientists-say-they-found-cause-of-blood-clotting-linked-to-astrazeneca-vaccine-11616169108?mod=flipboard&fbclid=IwAR0ui2eDUDr3ilyYdZaWyYzMgLofjKfW5b543rwBtiyImGT2Vf9RZeZu99w)
221 [linked-to-astrazeneca-vaccine-](https://www.wsj.com/articles/scientists-say-they-found-cause-of-blood-clotting-linked-to-astrazeneca-vaccine-11616169108?mod=flipboard&fbclid=IwAR0ui2eDUDr3ilyYdZaWyYzMgLofjKfW5b543rwBtiyImGT2Vf9RZeZu99w)
222 [11616169108?mod=flipboard&fbclid=IwAR0ui2eDUDr3ilyYdZaWyYzMgLofjKfW5b5](https://www.wsj.com/articles/scientists-say-they-found-cause-of-blood-clotting-linked-to-astrazeneca-vaccine-11616169108?mod=flipboard&fbclid=IwAR0ui2eDUDr3ilyYdZaWyYzMgLofjKfW5b543rwBtiyImGT2Vf9RZeZu99w)
223 [43rwBtiyImGT2Vf9RZeZu99w](https://www.wsj.com/articles/scientists-say-they-found-cause-of-blood-clotting-linked-to-astrazeneca-vaccine-11616169108?mod=flipboard&fbclid=IwAR0ui2eDUDr3ilyYdZaWyYzMgLofjKfW5b543rwBtiyImGT2Vf9RZeZu99w)] and later AstraZeneca was instructed to flag a possible

thrombotic side-effect of ChAdOx1 nCoV-19 vaccine on labelling [https://www.reuters.com/article/us-health-coronavirus-astrazeneca-statem/astrazeneca-to-flag-possible-blood-clot-side-effect-of-covid-19-vaccine-on-labelling-idUSKBN2BU2Z5] and recently, vaccine-induced immune thrombotic thrombocytopenia was coined to describe the pathogenesis of some of these cases[31].

Ironically, the same sequence of denial, investigations occurred with the Johnson & Johnson adenovirus vectored SARS CoV-2 Ad26.COV2-S vaccine as the FDA initially declared no causal thrombosis relationship is found [https://www.reuters.com/article/us-health-coronavirus-europe-vaccines/jj-covid-19-vaccine-under-eu-review-over-blood-clots-idUSKBN2BW2FI], but fortunately a prompt vigilant decision of a temporary pause of Ad26.COV2-S vaccine until further evaluation was issued [https://www.fda.gov/news-events/press-announcements/joint-cdc-and-fda-statement-johnson-johnson-covid-19-vaccine]. Notably, we have formally contacted the FDA before this pause emailing a draft of this manuscript and later, we urged it to respond like EMA and wisely they did [https://edition.cnn.com/2021/04/23/health/johnson-vaccine-acip-recommendation/index.html]. Interestingly, after some European countries have fully suspended the use of ChAdOx1 nCoV-19 vaccine, UK has restricted its use to people under 40 years old instead of those under 30 years old [https://www.reuters.com/world/uk/uk-advises-under-40s-take-alternative-astrazeneca-covid-19-shot-2021-05-07/] and started an analysis of its association with the autoimmune Guillain-Barré syndrome [https://www.reuters.com/business/healthcare-pharmaceuticals/eu-regulator-reviews-reports-rare-nervous-disorder-after-astrazeneca-vaccine-2021-05-07/]. Recently, the FDA has wisely labelled the Johnson & Johnson Ad26.COV2-S vaccine with a potential increased risk of Guillain-Barré syndrome [https://www.nytimes.com/2021/07/12/us/politics/fda-warning-johnson-johnson-vaccine-nerve-syndrome.html].

Unsurprisingly, British scientists have recently exposed that post SARS CoV-2 vaccines thrombotic events are not limited to the cerebral vasculature as splanchnic and portal vein thrombosis, with similar case fatality rate (18.8% versus 20% of cerebral venous thrombosis), within two weeks post vaccination are more common with BNT162b2 and

mRNA-1273 vaccines (44.9 per million versus 1.6 per million for their ChAdOx1 nCoV-19 vaccine) and though they have mentioned that the incidence is much higher after COVID-19 but we suggest that their comparison is not out of bias especially when properly adjusted for the affected age and gender [32,33] and one may wonder what else might be discovered by other researchers.

Moreover, we would like to suggest that a fatal autoimmune myocarditis, which is known to be underdiagnosed, might also be responsible for some of the post SARS CoV-2 mRNA vaccination sudden death reports which are being attributed to other conditions to acquire mRNA vaccine while they might be due to vaccine related myocarditis causing fatal arrhythmias, acute-onset heart failure with cardiogenic shock or pericardial effusion with cardiac tamponade [34,35]. Notably, a 19-year-old Israeli patient suffered from tachycardia, dyspnea, and angina like pain after receiving his second dose of BNT162b2 vaccine to be hospitalized five days later with a confirmed diagnosis of myocarditis. Importantly, since IL-6 has been suggested to play an integral role in the pathogenesis of clinical and experimental viral myocarditis[36,37], we would like to suggest that the potential clinical benefits of few days administration of NSAIDs [38] with SARS CoV-2 vaccines either concomitantly or on the day after both the first and second (if there is one) jabs might eventually exceed the inconclusive potential risk to lower the immune response developed from the vaccines[39]. Recently and fortunately, EMA has begun an investigation to assess the association between SARS CoV-2 mRNA vaccines and myocarditis though starting with the usual declaration that no indication at present that these cases were due to the vaccines [<https://www.reuters.com/business/healthcare-pharmaceuticals/eu-regulator-reviews-reports-rare-nervous-disorder-after-astrazeneca-vaccine-2021-05-07/>].

Moreover, an immunopathological phenomenon called antibody dependent enhancement (ADE) that might increase COVID-19 severity, discussed later, should be tested for a potential concomitant correlation in susceptible individuals e.g. some vaccines recipients who were previously primed by either SARS CoV-2 as silent infection or possibly through other commonly encountered corona viruses, might express an autoimmune lung reaction

which was suggested to reason for COVID-19 pathogenesis[10,40] and we suggest it might better suit COVID-19 complications whether or not linked to vaccination.

Furthermore, we would like to recommend CDC to urgently change its neutral recommendation and to advice against administration of nucleic acid-based vaccines to persons complaining from autoimmune diseases [<https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html>].

BNT162b2 vaccine potential extra risk

Importantly and unfortunately, the sequence used in BNT162b2 vaccine was suggested to induce misleading errors in translational decoding and protein synthesis which were hypothesized to produce serious long-term health damage including neurodegenerative diseases and multiple sclerosis[41]. Furthermore, several adjuvants, newly used in vaccines, are known to trigger the innate and adaptive immune system with a theoretical, not confirmed, risk to induce autoimmune diseases[11] and since most of the discussed serious adverse effects and fatalities were reported with the BNT162b2 vaccine, there is a likelihood for at least a short-term potential extra hazard that might be a company specific, to be fully explored and compared as regards to its sequence and used adjuvants to its mRNA-1273 counterpart as an essential component of any investigation. We also recommend consideration a sustained monitoring of the emergency approval granted by the FDA to BNT162b2 vaccine until all the claims against its design and its potential causation of some of the reported deaths are investigated and discussed.

Antibody dependent COVID-19 enhancement potential risk: vaccines and convalescent plasma links

Importantly, a risk for all types of SARS CoV-2 vaccines, especially the inactivated ones, that aim to develop antibodies against its spike protein is an immunopathological well recognized phenomenon called ADE which was reported and described with other respiratory and corona viruses including SARS CoV and MERS [10,42].

It was previously reported that in the presence of vaccine-elicited antiviral antibodies, SARS-CoV displayed an altered tropism toward primary human immune cells which were otherwise refractory to the virus. Furthermore, vaccines developed against animal

coronaviruses has demonstrated an immune enhancement of disease in vaccinated recipients[43]. Importantly, individuals suffering from severe COVID-19 were suggested to be primed by one or more prior coronavirus exposures, and due to antigenic epitope heterogeneity, are experiencing the effects of ADE similar to that previously postulated with SARS CoV[44]. Additionally, recurrent COVID-19 infection was described, in a significant minority due to a variable immune response, to be more severe and potentially fatal[45] and SARS CoV-2 vaccines were also suggested to possess the same immunological risk and a modification of their design was suggested to lower the potential risk[10] to be noted that abnormal immunological response to SARS CoV-2 BNT162b2 vaccine has been described and most likely predisposed to an accelerated SARS CoV-2 induced mortality[46]. Notably, a higher antibody titre against SARS-CoV-2 being was associated with more severe disease and suggested to be linked to ADE as one possible probability that was not excluded by the other suggested mechanisms. Moreover, several studies in murine and non-human primate models for SARS-CoV vaccines showed enhanced immunopathology, enhanced respiratory disease [47] or skewing immunological or inflammation-resolving response[42,48,49] on challenge with SARS CoV after immunization and thus the benefit of using SARS-CoV vaccine in humans was doubted[50] and a very interesting commentary that unfortunately has been unnoticed, possibly because of multiple prior rejections at more visible journals, has tested the outcomes of SARS CoV-2 infection in 33 African green monkeys which were vaccinated with mRNA SARS CoV-2 vaccines and ARDS has developed in one[51]. Moreover, it was recently announced that 60% of seriously ill COVID-19 Israeli patients were vaccinated with BNT162b2 vaccine and we suggest this might be considered as potential ADE as well as a clear evidence of the inefficacy of the current COVID-19 vaccines at least against the delta variant [<https://www.jpost.com/breaking-news/for-first-time-since-march-855-new-coronavirus-cases-in-israel-674084>].

Accordingly, we disagree with Fu et al. [52] in their suggestion that an early, sub-optimal neutralizing antibody activity reasons for ADE responsible for the severe SARS CoV induced pulmonary disease and with Lee et al.[47] in their suggestion, basing on interpretations of some murine models findings, that SARS CoV-2 vaccines that elicit high neutralizing antibody titres have a minimal risk of ADE which is supported by a preprinted

study that used a SARS CoV-2 murine model[53] as neutralizing antibodies are described to induce ADE [48,54] and a SARS CoV-2 DNA study that has been performed in non-human primates and frequently cited to acquit COVID-19 from ADE potential has clearly stated that it was not designed to examine safety issues. Furthermore, it recommended future studies to specifically address the probability of enhanced respiratory disease due to ADE implying that their favorable impression should never be cited as potentially conclusive[55].

Importantly, another argument that is also used as a principle to refute or underestimate COVID-19 ADE risk is that antibodies can have very different properties in animals compared to those in the human host, because of altered functional species-specific interactions between the antibody and immune cells[56]. However, this should be used likewise in favor of the contradictory perspective, and we also might likewise suggest that results coming from non-corona viruses should not be considered of much significant value when trying to interpret the potential risk of ADE in COVID-19. Moreover, we suggest that while COVID-19 does not worsen after treatment with plasma from convalescent patients[56], it should not be considered conclusive in a context that underestimates COVID-19 potential ADE risk for two reasons; the first is the timing as these antibodies are being administered to combat an ongoing infection and the other is that these antibodies might have worsened COVID-19 if proper validation of the reported cardiac events was conducted and thus an early ADE should not be excluded[57].

Interestingly, abundance of hospital admissions was described within seven days post SARS CoV-2 vaccination and it was hypothesized that this might occur with recently asymptomatic SARS CoV-2 infected patients who received the vaccines [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/982499/S1208_CO-

[CIN_report_on_impact_of_vaccination_Apr_21.pdf?fbclid=IwAR1wKZUaG9UOgYMs_vwbeQatY-aLG3eRz0mYFAMQxY5QF4xn3hlmtZxGWIV0](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/982499/S1208_CO-CIN_report_on_impact_of_vaccination_Apr_21.pdf?fbclid=IwAR1wKZUaG9UOgYMs_vwbeQatY-aLG3eRz0mYFAMQxY5QF4xn3hlmtZxGWIV0)] and we recommend investigating this hypothesis as it might eventually appear as a mild form of ADE. Alarming, unlike the one year spent to develop a vaccine for SARS CoV-2 (a single-stranded RNA virus), the journey to develop RSV (another enveloped non-segmented

single stranded RNA virus) vaccine took more than 60 years and has not ended yet. More alarmingly, 80% of young infants previously vaccinated with inactivated RSV who have been subsequently infected with wild RSV experienced enhanced respiratory disease that required hospitalization and two died and [58] and an atypical measles illness accompanied by peripheral edema and pneumonia occurred in ten children who had received inactivated measles (a third enveloped non-segmented single stranded RNA virus) vaccine five to six years earlier, and significant pleural effusions were noted in three of them[59]. Importantly, we wish to strongly recommend against any suggested administration of any SARS CoV-2 vaccine to children, especially the inactivated ones.

However, we confirm our recommendation using the lowest possible vaccination dose optimized to produce high-affinity anti-SARS CoV-2 IgG as this might be our route to decrease this and other potential likelihoods. Additionally, we reconfirm the need for developing suggested neutralizing nanobodies as well as new immunofocusing vaccines basing on the spike, N or other potential SARS CoV-2 immunological targets[42].

Finally, though reports of SARS CoV-2 infection early after vaccination have not reported ADE[60], yet the recent terrible surge of COVID-19 mortality in India should be further investigated whether SARS CoV-2 B.1.617 variants are the sole culprit or ADE might also be involved and whether the enthusiastic Indian vaccination program might promote the emergence of more lethal variants [61]. Notably, the timing of re-infection or vaccination might play a factor in development of ADE as well as some individualized immune-genetic factors and thus, from our point of view, a call for close and vigilant follow up should not be ignored and any report of such adverse effect should not be underestimated.

The potentially higher-risk groups and potential amelioration of the risks

Notably, we would like to explore some groups of individuals who are potentially more vulnerable to autoimmune diseases, aiming to recommend a personalized risk benefit ratio to be considered before a decision to be immunized by adenovirus and RNA based SARS CoV-2 vaccine until encouraging post marketing safety data are revealed for all SARS CoV-2 types of vaccines. The first higher-risk group are female[62] and this is a non-modifiable risk factor. However, reports of post SARS CoV-2 vaccination myocarditis seem to show male predominance in adolescents and young adults age 16 years or older

[<https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/myocarditis.html>] and the initial female predominance in reports of vaccine-induced immune thrombotic thrombocytopenia might have been skewed by the demographics of early vaccinated populations [<https://www.uptodate.com/contents/covid-19-vaccine-induced-immune-thrombotic-thrombocytopenia-vitt>].

The second group are smokers as cigarette smoke has been reported to lead to an enhanced risk of inflammatory and autoimmune diseases[63]. Notably, smokers are more likely to develop critical COVID-19 requiring mechanical ventilation [64] that might lead to a higher mortality rate [65,66]. Interestingly, alarms about the danger of misreading non-significant or inconclusive frequentist results containing several possible biases of a contradictory hypotheses have been raised [67,68].

Two other important groups that might be closely monitored include obese and diabetic individuals; obesity was suggested to be a major environmental factor contributing to the onset and progression of autoimmune diseases[69] and a concomitant autoimmune disease was encountered as 1 in 4 of 179,248 people diagnosed with type 1 diabetes[70]. Notably, a meta-analysis has showed diabetes, but not obesity, to be linked to a higher COVID-19 mortality[71]. However, increasing risks of COVID-19 hospital death were noticed to be associated with increasing levels of obesity (BMI >40 fully adjusted HR 2.27, 95% CI 1.99-2.58)[72] and an informed personalized risk benefit ratio must be secured.

Interestingly, quitting smoking at diagnosis was recently shown to decrease the risk of death in cancer patients[73], and quitting smoking was suggested to alleviate its impact in patients with pneumonia and other COVID-19 associated infections[66,68,74], thus a beneficial advice to quit smoking together with another to lose overweight and to control the blood glucose levels might also help to lower the chances of SARS CoV-2 adenovirus and RNA-based vaccine potential autoimmunity in those individuals.

Most importantly, we would like to stress the utmost importance to urge the participants to report all experienced adverse effects to a well-prepared post marketing surveillance system. Further, the search to improve methods that help to develop nucleic acid-based vaccines with minimal autoimmune potential risk should continue. However, as evolving

post marketing safety concerns are released, we recommend considering an individualized risk benefit ratio especially for those higher risk groups of patients.

Conclusion

In conclusion, we totally condemn, from a medical point of view, any national policy that necessitates these experimental vaccines and we also condemn the European Court of Human Rights shameful ruling that compulsory vaccination would not contravene human rights law [<https://www.dw.com/en/echr-rules-obligatory-vaccination-may-be-necessary/a-57128443>]. Moreover, though “experts” finally admit that their claimed vaccine induced herd immunity is very unlikely [75] or almost impossible [<https://www.nytimes.com/2021/05/03/health/covid-herd-immunity-vaccine.html>], they continue to make it almost compulsory and even advocate for vaccine passports. Alarming, we condemn the trials made by some pharmaceutical companies to test those vaccines in children as well as their attempt to seek clearance of usage in children aged two years and above [https://www.nytimes.com/2021/05/04/health/pfizer-vaccine-children-approval.html?action=click&block=associated_collection_recirc&impression_id=d81bf912-ad21-11eb-879f-e72e2db5680e&index=2&pgtype=Article®ion=footer] as other than the discovered potential short term complications, long term ones are not excluded as well [41]. Unsurprisingly, serious violations and manipulations of the trial protocol by which Pfizer has obtained FDA emergency authorization for administering its BNT162b2 vaccine to children have been published with no official reply [<https://americasfrontlinedoctors.org/frontlinenews/serious-violations-and-manipulations-of-trial-protocol-how-pfizer-obtained-fda-emergency-authorization-for-children/?fbclid=IwAR3Xi4--FGR7FMP6BfQ3i8w6Y7WFzdbiUYr5H4gAVzKpa22m0mp1M0p8FZI>] and recently other researchers have called for a reconsideration of the current “political” trend to vaccinate the children with SARS CoV-2 vaccines as they suggested a huge outbalance in their risk benefit ratio[4].

Alarming, NEJM has rejected to publish a logical comment that heavily criticized the integrity of the post SARS CoV-2 vaccination spontaneous abortion of 12.6% that came through counting 700 participants who received their first jab in the third trimester i.e. at a

time where no spontaneous abortion can occur [76] and unfortunately the authors had no alternative but to publish their comments revealing an actual rate of 82% at a nonacademic website

[http://www.skirsch.com/covid/Vaccine_safety_in_preg_NEJM_May_28_2021.pdf].

Notably, I was so fortunate to expose a similar NEJM bias, though for potentially toxic drugs, at an honorable journal[77]. Moreover, we would like to recommend following up the babies born to pregnant participants as long-term complications cannot be excluded and we consider their mothers' vaccination with these SARS CoV-2 vaccines as another crime against humanity.

Notably, we are regretful that many "honorable" journals, including one affiliated to the CDC, have refused to peer review this manuscript though a draft was submitted to many before the appearance of mortalities attributed to those vaccines and nothing changes when submitted to other journals after these mortalities have been discovered; no opportunity for a non-biased peer review was granted. Ironically, nothing is comparable to this misfortunate dishonorable academic misconduct, as I suggest, except the intended one year persistent denial, by dozens of similarly "reputable" journals to fairly review our immunomodulatory protocol that provides a safe, inexpensive cure to COVID-19 and even when it was accepted after peer review, some have intervened to remove it from publication[78].

Moreover, We urge the CDC to consider a change to its current recommendation to advise against use of nucleic acid based vaccination for COVID-19 patients complaining of autoimmune diseases and we suggest that FDA should investigate a potential extra risk that might be associated with BNT162b2 vaccine and calling for an independent re-evaluation of the post vaccination situation in Israel and we totally agree with the EMA and FDA decisions to reevaluate the safety of ChAdOx1 nCoV-19 and Ad26.COV2-S vaccines, respectively. Furthermore, that risk benefit ratio from administering convalescent plasma to COVID-19 patients might be outbalanced due to potential early ADE and a strict system for post vaccination surveillance must be secured to report any encountered serious adverse effect especially for those who would be reinfected with SARS CoV-2 despite vaccination. Additionally, the techniques used in development of all types of SARS CoV-2 vaccines,

especially the newly emergency approved ones, should focus on innovative methods to decrease their potential autoimmunity and antibody dependent disease enhancement. Finally, in all cases we believe that more careful consideration of these potential hazards must have been thoroughly discussed and/or refuted before a mass vaccination approval was granted under the cover of a so called “emergency” use approval as the public, which has been repeatedly denied a constitutional right to know, might not accept to sacrifice a minority of unaware recipients who experienced the presented serious adverse effects and/or mortalities who were denied their legal right to know first then decide. It should also be agreeable that no matter if SARS CoV-2 vaccines associated serious adverse effects are rare as frequently officially claimed or not so rare at all as non-peer reviewed extensive analysis might reveal [<http://www.skirsch.com/covid/Vaccine.pdf>], the right to know then freely decide is a must. Unfortunately, it is not yet excluded that political and/or economic gains might have shared to induce a man-made Hades, currently as in India or soon in other countries that might currently proclaim triumph, and we wish to remind all stakeholders that no prior agreements will, ever, secure impunity yet for the sake of millions of innocents who have been vaccinated though not in the high risk groups, I pray that my suspicions prove wrong.

Acknowledgments

This work is dedicated to Egypt; a country that I am proud to be one of its citizens, Africa; the continent that has suffered oppression for centuries and especially to my beloved mother to whom I owe my endurance and faith. The author would also like to sincerely thank Dr. James Lyons-Weiler (The Institute for Pure and Applied Knowledge; US) who after reading a preprint has generously emailed three valuable immunology related references that have enriched this and other manuscripts and I am also very grateful to Dr. Viera Malachovska, Ing, PhD a Slovakian scientist who has generously emailed precious links that discusses the safety concerns related to the BNT162b2 vaccine in Israel. I am also very much indebted to the precious feedback that has reached me from several individuals from many countries who have generously shared their reasonable doubt, fear and hopes after reading a preprint of this manuscript.

522 **Funding**

523 None

524 **Conflict of interest**

525 The author declares that he has no conflict of interest.

526 **References**

- 527 1. Kochhar S, Salmon DA. Planning for COVID-19 vaccines safety surveillance.
528 Vaccine. 2020 2020/09/11;38(40):6194-6198.
- 529 2. Petousis-Harris H. Assessing the Safety of COVID-19 Vaccines: A Primer. Drug
530 Safety. 2020 2020/09/30.
- 531 3. Shakir S, Lane S, Davies M. How to Investigate a Serious Adverse Event Reported
532 During a Clinical Trial for a COVID-19 Vaccine. Drug Safety. 2021
533 2021/01/01;44(1):1-5.
- 534 4. Walach H, Klement RJ, Aukema W. The Safety of COVID-19 Vaccinations—We
535 Should Rethink the Policy. Vaccines. 2021;9(7).
- 536 5. Takuva S, Takalani A, Garrett N, et al. Thromboembolic Events in the South
537 African Ad26.COV2.S Vaccine Study. New England Journal of Medicine. 2021.
- 538 6. Heidi Ledford. US authorization of first COVID vaccine marks new phase in safety
539 monitoring. Nature,. 2020, December 12;588:377-378.
- 540 7. Madhi SA, Baillie V, Cutland CL, et al. Safety and efficacy of the ChAdOx1 nCoV-
541 19 (AZD1222) Covid-19 vaccine against the B.1.351 variant in South Africa.
542 medRxiv. 2021:2021.02.10.21251247.
- 543 8. Bleier BS, Ramanathan M, Lane AP. COVID-19 Vaccines May Not Prevent Nasal
544 SARS-CoV-2 Infection and Asymptomatic Transmission. Otolaryngology–Head
545 and Neck Surgery. 2020 2021/02/01;164(2):305-307.
- 546 9. Kelleni M. SARS CoV-2 adenovirus and RNA based vaccines potential
547 autoimmune complications: could we lower the chances?. Authorea (Preprint)
548 2020. DOI: 10.22541/au.160677062.20686503/v1

- 549 10. Lyons-Weiler J. Pathogenic priming likely contributes to serious and critical illness
550 and mortality in COVID-19 via autoimmunity. *Journal of Translational*
551 *Autoimmunity*. 2020 2020/01/01/;3:100051.
- 552 11. Coffman RL, Sher A, Seder RA. Vaccine adjuvants: putting innate immunity to
553 work. *Immunity*. 2010;33(4):492-503.
- 554 12. Reuters (Ludwig Burger). AstraZeneca pauses coronavirus vaccine trial as
555 participant illness investigated 2020, September 09. Available from:
556 [https://www.reuters.com/article/us-health-coronavirus-astrazeneca/astrazeneca-](https://www.reuters.com/article/us-health-coronavirus-astrazeneca/astrazeneca-pauses-coronavirus-vaccine-trial-rollout-doubts-dent-shares-idUSKBN26017L)
557 [pauses-coronavirus-vaccine-trial-rollout-doubts-dent-shares-idUSKBN26017L](https://www.reuters.com/article/us-health-coronavirus-astrazeneca/astrazeneca-pauses-coronavirus-vaccine-trial-rollout-doubts-dent-shares-idUSKBN26017L)
- 558 13. Statnews (MATTHEW HERPER). Covid-19 vaccine trials from AstraZeneca,
559 Johnson & Johnson to restart 2020, October 23. Available from:
560 [https://www.statnews.com/2020/10/23/covid-19-vaccine-trials-from-astrazeneca-](https://www.statnews.com/2020/10/23/covid-19-vaccine-trials-from-astrazeneca-johnson-johnson-to-restart/)
561 [johnson-johnson-to-restart/](https://www.statnews.com/2020/10/23/covid-19-vaccine-trials-from-astrazeneca-johnson-johnson-to-restart/)
- 562 14. Ledford SMH. COVID-vaccine results are on the way — and scientists’ concerns
563 are growing. *Nature*. 2020, September 25. Available from:
564 <https://www.nature.com/articles/d41586-020-02706-6>
- 565 15. Reuters. J&J pauses COVID-19 vaccine trials due to unexplained illness in
566 participant 2020, October 13. Available from: [https://www.reuters.com/article/uk-](https://www.reuters.com/article/uk-health-coronavirus-johnson-johnson/jj-pauses-covid-19-vaccine-trials-due-to-unexplained-illness-in-participant-idUKKBN26Y02L)
567 [health-coronavirus-johnson-johnson/jj-pauses-covid-19-vaccine-trials-due-to-](https://www.reuters.com/article/uk-health-coronavirus-johnson-johnson/jj-pauses-covid-19-vaccine-trials-due-to-unexplained-illness-in-participant-idUKKBN26Y02L)
568 [unexplained-illness-in-participant-idUKKBN26Y02L](https://www.reuters.com/article/uk-health-coronavirus-johnson-johnson/jj-pauses-covid-19-vaccine-trials-due-to-unexplained-illness-in-participant-idUKKBN26Y02L)
- 569 16. The New York Times (Rebecca Robbins and Benjamin Mueller). After Admitting
570 Mistake, AstraZeneca Faces Difficult Questions About Its Vaccine 2020,
571 November 25. Available from:
572 [https://www.nytimes.com/2020/11/25/business/coronavirus-vaccine-astrazeneca-](https://www.nytimes.com/2020/11/25/business/coronavirus-vaccine-astrazeneca-oxford.html)
573 [oxford.html](https://www.nytimes.com/2020/11/25/business/coronavirus-vaccine-astrazeneca-oxford.html)
- 574 17. Wagner TE, Becraft JR, Bodner K, et al. Small-molecule-based regulation of RNA-
575 delivered circuits in mammalian cells. *Nature Chemical Biology*. 2018
576 2018/11/01;14(11):1043-1050.
- 577 18. Wen Y-M, Mu L, Shi Y. Immunoregulatory functions of immune complexes in
578 vaccine and therapy. *EMBO Mol Med*. 2016;8(10):1120-1133.

- 579 19. Zhang C, Maruggi G, Shan H, et al. Advances in mRNA Vaccines for Infectious
580 Diseases [Review]. *Frontiers in Immunology*. 2019 2019-March-27;10(594).
- 581 20. Pardi N, Hogan MJ, Porter FW, et al. mRNA vaccines — a new era in vaccinology.
582 *Nature Reviews Drug Discovery*. 2018 2018/04/01;17(4):261-279.
- 583 21. Andries O, Kitada T, Bodner K, et al. Synthetic biology devices and circuits for
584 RNA-based ‘smart vaccines’: a propositional review. *Expert Review of Vaccines*.
585 2015 2015/02/01;14(2):313-331.
- 586 22. Wang F, Kream RM, Stefano GB. An Evidence Based Perspective on mRNA-
587 SARS-CoV-2 Vaccine Development. *Med Sci Monit*. 2020;26:e924700-e924700.
- 588 23. Bloom K, van den Berg F, Arbuthnot P. Self-amplifying RNA vaccines for
589 infectious diseases. *Gene Therapy*. 2020 2020/10/22.
- 590 24. NTV. Zusammenhang unwahrscheinlich: Institut prüft zehn Todesfälle nach
591 Impfung [German]. 2021, January 14.
- 592 25. Guo L, Rondina MT. The Era of Thromboinflammation: Platelets Are Dynamic
593 Sensors and Effector Cells During Infectious Diseases. *Front Immunol*.
594 2019;10:2204.
- 595 26. Hoffman M, Monroe DM, Roubey RA. Links between the immune and coagulation
596 systems: how do "antiphospholipid antibodies" cause thrombosis? *Immunol Res*.
597 2000;22(2-3):191-7.
- 598 27. Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate
599 immunity. *Nature Reviews Immunology*. 2013 2013/01/01;13(1):34-45.
- 600 28. Tamaki H, Khasnis A. Venous thromboembolism in systemic autoimmune
601 diseases: A narrative review with emphasis on primary systemic vasculitides.
602 *Vascular Medicine*. 2015 2015/08/01;20(4):369-376.
- 603 29. Aggarwal S, Sharma N. Cerebral venous sinus thrombosis with autoimmune
604 thyroiditis. *Indian J Endocrinol Metab*. 2013;17(Suppl 1):S176-S177.
- 605 30. Carhuapoma Juan R, Mitsias P, Levine Steven R. Cerebral Venous Thrombosis and
606 Anticardiolipin Antibodies. *Stroke*. 1997 1997/12/01;28(12):2363-2369.
- 607 31. Greinacher A, Thiele T, Warkentin TE, et al. Thrombotic Thrombocytopenia after
608 ChAdOx1 nCov-19 Vaccination. *New England Journal of Medicine*. 2021.

609 32. See I, Su JR, Lale A, et al. US Case Reports of Cerebral Venous Sinus Thrombosis
610 With Thrombocytopenia After Ad26.COVS.2.S Vaccination, March 2 to April 21,
611 2021. JAMA. 2021.

612 33. Maxime Taquet MH, John R Geddes, Sierra Luciano, Paul J Harrison. Cerebral
613 venous thrombosis: a retrospective cohort study of 513,284 confirmed COVID-19
614 cases and a comparison with 489,871 people receiving a COVID-19 mRNA
615 vaccine. OSFPREPRINTS (Preprint). 2021.

616 34. Bracamonte-Baran W, Čiháková D. Cardiac Autoimmunity: Myocarditis. Adv Exp
617 Med Biol. 2017;1003:187-221.

618 35. Khalil A, Naneishvili T, Prasad N, et al. SARS-CoV-2 myocarditis: what
619 physicians need to know. BMJ Evidence-Based Medicine. 2021:bmjebm-2020-
620 111527.

621 36. Esfandiarei M, McManus BM. Molecular Biology and Pathogenesis of Viral
622 Myocarditis. Annual Review of Pathology: Mechanisms of Disease. 2008
623 2008/02/01;3(1):127-155.

624 37. Savvatis K, Müller I, Fröhlich M, et al. Interleukin-6 receptor inhibition modulates
625 the immune reaction and restores titin phosphorylation in experimental
626 myocarditis. Basic Research in Cardiology. 2014 2014/10/25;109(6):449.

627 38. Kelleni MT. NSAIDs/Nitazoxanide/Azithromycin Repurposed for COVID-19:
628 Potential Mitigation of the Cytokine Storm Interleukin-6 Amplifier via
629 Immunomodulatory Effects. Expert Review of Anti-infective Therapy. 2021. DOI:
630 10.1080/14787210.2021.1939683.

631 39. Saleh E, Moody MA, Walter EB. Effect of antipyretic analgesics on immune
632 responses to vaccination. Human vaccines & immunotherapeutics.
633 2016;12(9):2391-2402.

634 40. Karaderi T, Bareke H, Kunter I, et al. Host Genetics at the Intersection of
635 Autoimmunity and COVID-19: A Potential Key for Heterogeneous COVID-19
636 Severity [Perspective]. Front Immunol. 2020 2020-December-22;11(3314).

637 41. Kira Smith. BNT162b2 Vaccine: Possible Codons Misreading, Errors in Protein
638 Synthesis and Alternative Splicing's Anomalies. Journal of Antivirals &
639 Antiretrovirals. 2021;13(2).

- 640 42. Karthik K, Senthilkumar TMA, Udhayavel S, et al. Role of antibody-dependent
641 enhancement (ADE) in the virulence of SARS-CoV-2 and its mitigation strategies
642 for the development of vaccines and immunotherapies to counter COVID-19.
643 Human Vaccines & Immunotherapeutics. 2020 2020/12/01;16(12):3055-3060.
- 644 43. Yip MS, Leung NHL, Cheung CY, et al. Antibody-dependent infection of human
645 macrophages by severe acute respiratory syndrome coronavirus. Virol J.
646 2014;11:82-82.
- 647 44. Tetro JA. Is COVID-19 receiving ADE from other coronaviruses? Microbes Infect.
648 2020;22(2):72-73.
- 649 45. Adrielle dos Santos L, Filho PGdG, Silva AMF, et al. Recurrent COVID-19
650 including evidence of reinfection and enhanced severity in thirty Brazilian
651 healthcare workers. Journal of Infection.
- 652 46. Hansen T, Titze U, Kulamadayil-Heidenreich NSA, et al. First case of postmortem
653 study in a patient vaccinated against SARS-CoV-2. International Journal of
654 Infectious Diseases. 2021 2021/06/01;107:172-175.
- 655 47. Lee WS, Wheatley AK, Kent SJ, et al. Antibody-dependent enhancement and
656 SARS-CoV-2 vaccines and therapies. Nature Microbiology. 2020
657 2020/10/01;5(10):1185-1191.
- 658 48. Liu L, Wei Q, Lin Q, et al. Anti-spike IgG causes severe acute lung injury by
659 skewing macrophage responses during acute SARS-CoV infection. JCI Insight.
660 2019;4(4):e123158.
- 661 49. Tseng CT, Sbrana E, Iwata-Yoshikawa N, et al. Immunization with SARS
662 coronavirus vaccines leads to pulmonary immunopathology on challenge with the
663 SARS virus. PLoS One. 2012;7(4):e35421.
- 664 50. Yip MS, Cheung CY, Li PH, et al. Investigation of Antibody-Dependent
665 Enhancement (ADE) of SARS coronavirus infection and its role in pathogenesis of
666 SARS. BMC Proceedings. 2011 2011/01/10;5(1):P80.
- 667 51. Farshi E. Cytokine Storm Response to COVID-19 Vaccinations. Journal of
668 Cytokine Biology. 2020;5: 1000125

669

670 52. Fu Y, Cheng Y, Wu Y. Understanding SARS-CoV-2-Mediated Inflammatory
671 Responses: From Mechanisms to Potential Therapeutic Tools. *Virologica Sinica*.
672 2020 2020/06/01;35(3):266-271.

673 53. Quinlan BD, Mou H, Zhang L, et al. The SARS-CoV-2 receptor-binding domain
674 elicits a potent neutralizing response without antibody-dependent enhancement.
675 *bioRxiv*. 2020:2020.04.10.036418.

676 54. Iwasaki A, Yang Y. The potential danger of suboptimal antibody responses in
677 COVID-19. *Nat Rev Immunol*. 2020;20(6):339-341.

678 55. Yu J, Tostanoski LH, Peter L, et al. DNA vaccine protection against SARS-CoV-2
679 in rhesus macaques. *Science*. 2020;369(6505):806-811.

680 56. Arvin AM, Fink K, Schmid MA, et al. A perspective on potential antibody-
681 dependent enhancement of SARS-CoV-2. *Nature*. 2020
682 2020/08/01;584(7821):353-363.

683 57. Pathak EB. Convalescent plasma is ineffective for covid-19. *BMJ*.
684 2020;371:m4072.

685 58. Mejias A, Rodríguez-Fernández R, Oliva S, et al. The journey to a respiratory
686 syncytial virus vaccine. *Annals of Allergy, Asthma & Immunology*.
687 2020;125(1):36-46.

688 59. Fulginiti VA, Eller JJ, Downie AW, et al. Altered Reactivity to Measles Virus:
689 Atypical Measles in Children Previously Immunized With Inactivated Measles
690 Virus Vaccines. *JAMA*. 1967;202(12):1075-1080.

691 60. Amit S BS, Biber A, Grinberg A, Leshem E, Regev-Yochay G. . Post-vaccination
692 COVID-19 among healthcare workers, Israel. *Emerg Infect Dis*. 2021.

693 61. Williams TC, Burgers WA. SARS-CoV-2 evolution and vaccines: cause for
694 concern? *The Lancet Respiratory Medicine*. 2021;9(4):333-335.

695 62. Angum F, Khan T, Kaler J, et al. The Prevalence of Autoimmune Disorders in
696 Women: A Narrative Review. *Cureus*. 2020;12(5):e8094-e8094.

697 63. Hussain MS, Tripathi V. Smoking under hypoxic conditions: a potent
698 environmental risk factor for inflammatory and autoimmune diseases. *Mil Med*
699 *Res*. 2018 Mar 30;5(1):11.

700 64. Adrish M, Chilimuri S, Mantri N, et al. Association of smoking status with
701 outcomes in hospitalised patients with COVID-19. *BMJ Open Respir Res.* 2020
702 Oct;7(1).

703 65. Jimenez-Ruiz CA, Lopez-Padilla D, Alonso-Arroyo A, et al. COVID-19 and
704 Smoking: A Systematic Review and Meta-Analysis of the Evidence. *Arch*
705 *Bronconeumol.* 2020 Jul 25.

706 66. Patanavanich R, Glantz SA. Smoking is associated with worse outcomes of
707 COVID-19 particularly among younger adults: A systematic review and meta-
708 analysis. *medRxiv.* 2020 Sep 23.

709 67. Usman MS, Siddiqi TJ, Khan MS, et al. Is there a smoker's paradox in COVID-
710 19? *BMJ Evidence-Based Medicine.* 2020:bmjebm-2020-111492.

711 68. Carmona-Bayonas A, Jimenez-Fonseca P, Sánchez Arraez Á, et al. Does active
712 smoking worsen Covid-19? *Eur J Intern Med.* 2020;77:129-131.

713 69. Versini M, Jeandel PY, Rosenthal E, et al. Obesity in autoimmune diseases: not a
714 passive bystander. *Autoimmun Rev.* 2014 Sep;13(9):981-1000.

715 70. Rogers MAM, Wei MY, Kim C, et al. Sex Differences in Autoimmune
716 Multimorbidity in Type 1 Diabetes Mellitus and the Risk of Cardiovascular and
717 Renal Disease: A Longitudinal Study in the United States, 2001-2017. *J Womens*
718 *Health (Larchmt).* 2020 Apr;29(4):511-519.

719 71. Figliozi S, Masci PG, Ahmadi N, et al. Predictors of adverse prognosis in COVID-
720 19: A systematic review and meta-analysis [<https://doi.org/10.1111/eci.13362>].
721 *European Journal of Clinical Investigation.* 2020 2020/10/01;50(10):e13362.

722 72. Williamson E, Walker AJ, Bhaskaran KJ, et al. OpenSAFELY: factors associated
723 with COVID-19-related hospital death in the linked electronic health records of 17
724 million adult NHS patients. *medRxiv.* 2020:2020.05.06.20092999.

725 73. Yang S, Liu T, Liang G. The benefits of smoking cessation on survival in cancer
726 patients by integrative analysis of multi-omics data. *Mol Oncol.* 2020 Jun 24.

727 74. CDC. Coronavirus Disease 2019 (COVID-19): People with Certain Medical
728 Conditions 2020, November 02. Available from:
729 [https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-](https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html#smoking)
730 [medical-conditions.html#smoking](https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html#smoking)

- 731 75. Grant A, Hunter PR. Immunisation, asymptomatic infection, herd immunity and
732 the new variants of COVID 19. medRxiv. 2021:2021.01.16.21249946.
- 733 76. Shimabukuro TT, Kim SY, Myers TR, et al. Preliminary Findings of mRNA Covid-
734 19 Vaccine Safety in Pregnant Persons. New England Journal of Medicine. 2021
735 2021/06/17;384(24):2273-2282.
- 736 77. Kelleni MT. Tocilizumab, Remdesivir, Favipiravir, and Dexamethasone
737 Repurposed for COVID-19: a Comprehensive Clinical and Pharmacovigilant
738 Reassessment. SN Compr Clin Med. 2021 2021/04/01;3(4):919-923.
- 739 78. Kelleni M. NSAIDs/Nitazoxanide/Azithromycin Immunomodulatory Protocol
740 Used in Adults, Geriatric, Pediatric, Pregnant, and Immunocompromised COVID-
741 19 Patients: A Prospective Observational Study and Case-Series. Authorea
742 (Preprint) 2021 DOI: 1022541/au16212660115715282/v5.